<DOC>
	<DOCNO>NCT00006054</DOCNO>
	<brief_summary>OBJECTIVES : I . Provide curative immunoreconstituting allogeneic bone marrow transplantation patient primary immunodeficiency . II . Determine relevant outcome treatment patient include quality survival , extent morbidity mortality complication treatment ( e.g. , graft versus host disease , regimen related toxicity , B- cell lymphoproliferative disease ) , completeness functional immunoreconstitution .</brief_summary>
	<brief_title>Allogeneic Bone Marrow Transplantation Patients With Primary Immunodeficiencies</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients severe combine immunodeficiency ( SCID ) use match sibling donor receive allogeneic bone marrow umbilical cord blood transplantation day 0 . Patients receive graft versus host disease ( GVHD ) prophylaxis methotrexate IV day 1 , 3 , 6 , 11 cyclosporine IV day -3 50 . Patients SCID use donor histocompatible sibling , Wiskott Aldrich syndrome use histocompatible sibling donor , Wiskott Aldrich syndrome 5 year age use donor histocompatible sibling , X-linked CD40 ligand deficiency use histocompatible sibling donor , X-linked CD40 ligand deficiency 5 year age use donor histocompatible sibling , primary immunodeficiency without manifestation hemophagocytosis use histocompatible sibling donor , primary immunodeficiency without manifestation hemophagocytosis 5 year age use donor histocompatible sibling receive busulfan IV 2 hour every 6 hour day -9 -6 , cyclophosphamide IV day -5 -2 , antithymocyte globulin ( ATG ) twice daily day -4 -1 . Allogeneic bone marrow umbilical cord blood transplantation take place day 0 . Patients receive graft versus host disease ( GVHD ) prophylaxis methotrexate IV day 1 , 3 , 6 , 11 cyclosporine IV day -3 50 . Patients hemophagocytic lymphohistiocytosis , Chediak Higashi syndrome , X-linked lymphoproliferative syndrome , severe progressive Langerhans cell histiocytosis , primary immunodeficiency complication hemophagocytosis receive busulfan IV 2 hour every 6 hour day -9 -6 , cyclophosphamide IV 2 hour day -5 -2 , etoposide IV 22 hour day -5 -3 , ATG IV twice daily day -2 , -1 , 1 , 2 . Allogeneic bone marrow umbilical cord blood transplantation take place day 0 . Patients receive graft versus host disease ( GVHD ) prophylaxis methotrexate IV day 1 , 3 , 6 , 11 cyclosporine IV day -3 50 . Patients Wiskott Aldrich syndrome primary immunodeficiency without manifestation hemophagocytosis , 5 year age use donor histocompatible sibling , receive busulfan IV 2 hour every 6 hour day -6 -5 , cyclophosphamide IV 2 hour day -4 -3 , total body irradiation day -2 , ATG IV 2 hour twice daily day -2 , -1 , 2 , 3 . Allogeneic bone marrow umbilical cord blood transplantation take place day 0 1 . Patients receive GVHD prophylaxis methylprednisolone IV every 12 hour day 2-21 , oral prednisone every 12 hour day 22-100 tapered day 101 128 , cyclosporine IV 2 hour every 8-12 hour day -3 100 . All patient follow determined primary physician .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Tissue Adhesions</mesh_term>
	<mesh_term>Granulomatous Disease , Chronic</mesh_term>
	<mesh_term>Granuloma</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<mesh_term>Lymphohistiocytosis , Hemophagocytic</mesh_term>
	<mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>Chediak-Higashi Syndrome</mesh_term>
	<mesh_term>Hyper-IgM Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Hyper-IgM Immunodeficiency Syndrome , Type 1</mesh_term>
	<mesh_term>Genetic Diseases , X-Linked</mesh_term>
	<mesh_term>Leukocyte-Adhesion Deficiency Syndrome</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Severe combine immunodeficiency All age histocompatible sibling donor donor OR Wiskott Aldrich syndrome All age histocompatible sibling donor donor OR Xlinked CD40 ligand deficiency All age histocompatible sibling donor OR Under 5 year age donor histocompatible sibling OR Other primary immunodeficiency without manifestation hemophagocytosis All age histocompatible sibling donor donor OR Hemophagocytic lymphohistiocytosis ( HLH ) Familial erythrophagocytic lymphohistiocytosis ( FEL ) , familial HLH ( FHLH ) , recurrent virusassociated hemophagocytic syndrome ( VAHS ) All age relate unrelated donor OR Chediak Higashi syndrome All age relate unrelated donor OR Xlinked lymphoproliferative syndrome All age relate unrelated donor OR Other primary immunodeficiency complication hemophagocytosis All age relate unrelated donor OR Severe progressive Langerhans cell histiocytosis All age relate unrelated donor</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2003</verification_date>
	<keyword>Chediak-Higashi syndrome</keyword>
	<keyword>Langerhans cell histiocytosis</keyword>
	<keyword>Wiskott-Aldrich syndrome</keyword>
	<keyword>X-linked agammaglobulinemia</keyword>
	<keyword>X-linked hyper IgM syndrome</keyword>
	<keyword>X-linked lymphoproliferative syndrome</keyword>
	<keyword>chronic granulomatous disease</keyword>
	<keyword>common variable immunodeficiency</keyword>
	<keyword>complement deficiency</keyword>
	<keyword>disease-related problem/condition</keyword>
	<keyword>familial erythrophagocytic lymphohistiocytosis</keyword>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>hematologic disorder</keyword>
	<keyword>hemophagocytic lymphohistiocytosis</keyword>
	<keyword>histiocytosis</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>leukocyte adhesion deficiency syndrome</keyword>
	<keyword>primary immunodeficiency disease</keyword>
	<keyword>rare disease</keyword>
	<keyword>severe combine immunodeficiency</keyword>
	<keyword>virus-associated hemophagocytic syndrome</keyword>
</DOC>